SCHEMBL454068

SCHEMBL454068

CCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.61
ALDH1A1 P00352 1/20 0.54
MAPT P10636 3/20 0.53
MAPK1 P28482 2/20 0.53
PAM P19021 2/20 0.50
PRKCA P17252 1/20 0.50
PRKCE Q02156 1/20 0.50
PRKCQ Q04759 1/20 0.50
PRKCD Q05655 1/20 0.50
DGKA P23743 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.49
DUSP3 P51452 1/20 0.49
GMNN O75496 1/20 0.47
HSP90AA1 P07900 1/20 0.47
BLM P54132 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NR1H4 Q96RI1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30104624 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL465544 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL30104654 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL19821495 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL18206768 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL19931336 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL465547 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL19821494 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL465548 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM
SCHEMBL30104676 1.00 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 906 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743053-A1 ANTIMICROBIAL SYNERGIES Symrise AG (DE) 2026-05-20 EP claimed
US-20260130785-A1 SYSTEMS AND METHODS INCLUDING LUBRICANTS FOR CONVEYANCE OF STOOL LIQUIGLIDE INC (US) 2026-05-14 US claimed
EP-4731736-A1 COMPOSITION COMPRISING BIOSURFACTANT AND MANGANESE Evonik Operations GmbH (DE) 2026-04-29 EP claimed
US-12576018-B2 Active agents for skin and hair care with sensory modifying properties SYMRISE AG (DE) 2026-03-17 US claimed
EP-4554551-B1 3-HYDROXYPROPYLESTERS AS ANTIMICROBIAL AGENTS SYMRISE AG (DE) 2026-03-11 EP claimed
US-20260041094-A1 Compositions Comprising an Antimicrobial Boosting Agent SYMRISE AG (DE) 2026-02-12 US claimed
EP-3530262-B1 PERSONAL CARE COMPOSITIONS AND USES PROCTER & GAMBLE (US) 2026-01-14 EP claimed
EP-4419065-B1 FRAGRANCING COMPLEX, FRAGRANCING COMPOSITION AND FRAGRANCED AQUEOUS COMPOSITION OF NATURAL ORIGIN EXPRESSIONS PARFUMEES (FR) 2025-12-03 EP claimed
US-12486996-B2 Antimicrobial composition including an acyl lactylate and a glycol and methods of inhibiting microbial growth utilizing the same KIMBERLY-CLARK WORLDWIDE, INC. (US) 2025-12-02 US claimed
EP-4616840-A2 COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS WITH ANTIMICROBIALS FOR PRODUCT PROTECTION Symrise AG (DE) 2025-09-17 EP claimed
EP-1100476-A1 FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FENOLDOPAM ALZA CORPORATION (US) 2001-05-23 EP claimed
WO-2000004886-A1 FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FENOLDOPAM ALZA CORPORATION (US) 2000-02-03 WO claimed
EP-0976391-A1 Cosmetic and dermatological W/O emulsions, containing ionic and/or amphoteric detergents and the presence of an amount of silicone-emulgators Beiersdorf Aktiengesellschaft (DE) 2000-02-02 EP claimed
US-6004578-A FOR ENHANCING THE PERCUTANEOUS ABSORPTION OF DRUGS WHEN ADMINISTERED TO A BODY SURFACE OR MEMBRANE ALZA CORPORATION (US) 1999-12-21 US claimed
EP-0934078-A2 PERMEATION ENHANCERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS, DEVICES, AND METHODS ALZA CORPORATION (US) 1999-08-11 EP claimed
WO-1999032096-A1 NOVEL FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF ASIMADOLINE ALZA CORPORATION (US) 1999-07-01 WO claimed
US-5882676-A Skin permeation enhancer compositions using acyl lactylates ALZA CORPORATION (US) 1999-03-16 US claimed
WO-1998017315-A2 PERMEATION ENHANCERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS, DEVICES, AND METHODS ALZA CORPORATION (US) 1998-04-30 WO claimed
EP-0828516-A1 SKIN PERMEATION ENHANCER COMPOSITIONS USING ACYL LACTYLATES ALZA CORPORATION (US) 1998-03-18 EP claimed
WO-1996037231-A1 SKIN PERMEATION ENHANCER COMPOSITIONS USING ACYL LACTYLATES ALZA CORPORATION (US) 1996-11-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260130785-A1 SYSTEMS AND METHODS INCLUDING LUBRICANTS FOR CONVEYANCE OF STOOL MUC1, LPO, UBE3A LMNA 4378/4885ALDH1A1 623/4885MAPT 4051/4885
US-20260041094-A1 Compositions Comprising an Antimicrobial Boosting Agent TLR7, MYC, ERG28 LMNA 4342/4885ALDH1A1 4611/4885MAPT 4723/4885
US-12576018-B2 Active agents for skin and hair care with sensory modifying properties SCD5, SMURF1, SGMS1 LMNA 1716/4885ALDH1A1 2828/4885MAPT 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.